BreezeBio

GenEdit's mission is to develop curative therapies through in vivo delivery of gene medicines and to enable the next generation of CRISPR-based gene therapies. Our non-viral, non-lipid polymer nanoparticle NanoGalaxy™ platform will provide significant opportunities for launching the next generation of safe and effective gene medicines. To bring these medicines to patients, we are developing our own internal pipeline and providing various therapeutic payloads for our partners' projects. With the collective expertise of our team, we are currently advancing new therapies and ushering in a new era of genetic medicine: we can edit diseases and rewrite patient health.